Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRD-guided azacitidine after allogeneic stem cell transplantation in myelodysplastic syndrome
2021-003809-22Phase 2Active
- Sponsor
- Karolinska University Hospital
- Start
- Aug 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of azacitidine in myelodysplastic syndrome (MDS), sponsored by Karolinska University Hospital. Started Aug 2022; status: active.
02
Drugs
azacitidine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2021-003809-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003809-22.